Capital Advisors Ltd’s Novavax NVAX Stock Holding History

Capital Advisors Ltd’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-30	Closed	-$1K	–	1505
2022 Q3	$1K	Buy	+30	New	+$1.3K	﹤0.01%	1074
2022 Q1	–	Sell	-1	Closed	–	–	1118
2021 Q4	$0	Buy	+1	New	+$172	﹤0.01%	897

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HIG

Herr Investment Group Austin, Texas $1.5B AUM 29.27% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital Advisors Ltd's NVAX Position: Q4 2022 in Review

Capital Advisors Ltd sold out of Novavax (NVAX) in Q4 2022, closing a stake of 30 shares — an estimated $1K sold.

Capital Advisors Ltd first reported a position in NVAX in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q3 2022. 252 funds tracked by Wall St. Rank hold NVAX as of Q4 2022.

Capital Advisors Ltd reported no remaining Novavax position as of Q4 2022 after selling out during the quarter.
Capital Advisors Ltd sold 30 Novavax shares in Q4 2022, an estimated $1K.
Capital Advisors Ltd first reported a position in Novavax in Q4 2021 and held it in 2 quarters.
Capital Advisors Ltd's Novavax position peaked at $1K in Q3 2022.
252 funds tracked by Wall St. Rank held Novavax as of Q4 2022.

Based on Capital Advisors Ltd's 13F filing for Q4 2022, filed 7 Feb 2023.